Clay Siegall Insider Deal for 18,832 Shares of Seattle Genetics, Inc. (SGEN); Nuveen Short Duration Credit Opportunities Fund Has 1 Sentiment

June 13, 2018 - By Ann Lacey

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

Nuveen Short Duration Credit Opportunities Fund (JSD) investors sentiment decreased to 1 in Q1 2018. It’s down -0.14, from 1.14 in 2017Q4. The ratio worsened, as 14 funds started new or increased equity positions, while 14 trimmed and sold equity positions in Nuveen Short Duration Credit Opportunities Fund. The funds in our database now have: 2.52 million shares, down from 2.54 million shares in 2017Q4. Also, the number of funds holding Nuveen Short Duration Credit Opportunities Fund in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 8 Increased: 12 New Position: 2.

The stock increased 0.86% or $0.15 during the last trading session, reaching $17.57. About 9,594 shares traded. Nuveen Short Duration Credit Opportunities Fund (JSD) has 0.00% since June 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Comerica Securities Inc holds 0.24% of its portfolio in Nuveen Short Duration Credit Opportunities Fund for 113,908 shares. Camelot Portfolios Llc owns 15,000 shares or 0.12% of their US portfolio. Moreover, Advisors Asset Management Inc. has 0.08% invested in the company for 284,007 shares. The Minnesota-based Sit Investment Associates Inc has invested 0.05% in the stock. Freestone Capital Holdings Llc, a Washington-based fund reported 25,342 shares.

A calculated and judicious move was made by the President and CEO of Seattle Genetics Inc Wa, Mr. Clay Siegall, 2 days ago, when he unloaded number of shares – 18,832, totalling $1,226,341 US Dollars, estimated based on $65.1 for a share. The stock trade by Mr. Clay – was dated on June 12, 2018 and made public in a SEC’s document available here. Clay now has ownership of 687,146 shares accounting for 0.43% of the Company’s market cap

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $10.92 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Seattle Genetics has $77.0 highest and $4300 lowest target. $63.40’s average target is -8.12% below currents $69 stock price. Seattle Genetics had 68 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was initiated by Goldman Sachs with “Sell” on Wednesday, November 18. The firm has “Buy” rating given on Friday, October 27 by RBC Capital Markets. The firm has “Hold” rating given on Thursday, July 27 by Cowen & Co. Goldman Sachs upgraded the shares of SGEN in report on Thursday, September 15 to “Neutral” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Underperform” rating given on Friday, February 10 by Bank of America. As per Monday, November 13, the company rating was maintained by RBC Capital Markets. Piper Jaffray upgraded Seattle Genetics, Inc. (NASDAQ:SGEN) on Friday, October 30 to “Neutral” rating. The stock has “Buy” rating by Jefferies on Monday, June 12. The firm earned “Hold” rating on Tuesday, October 3 by SunTrust. Barclays Capital initiated it with “Overweight” rating and $51 target in Thursday, February 4 report.

More recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: which released: “Premarket analyst action – healthcare” on June 11, 2018. Also published the news titled: “Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or ..” on June 13, 2018.‘s news article titled: “10 Biggest Price Target Changes For Monday” with publication date: June 11, 2018 was also an interesting one.

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on July, 26. They expect $-0.34 EPS, up 12.82% or $0.05 from last year’s $-0.39 per share. After $-0.61 actual EPS reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts -44.26% EPS growth.

Investors sentiment increased to 1.61 in 2018 Q1. Its up 0.38, from 1.23 in 2017Q4. It increased, as 24 investors sold Seattle Genetics, Inc. shares while 53 reduced holdings. 31 funds opened positions while 93 raised stakes. 159.52 million shares or 12.47% more from 141.83 million shares in 2017Q4 were reported. Profund Advsrs Ltd Com owns 35,115 shares. Vanguard Inc holds 8.63M shares or 0.02% of its portfolio. Cubist Systematic Strategies Ltd Liability owns 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 3,735 shares. Emory University accumulated 48,079 shares. California-based Bedell Frazier Investment Counseling Limited Liability has invested 2.06% in Seattle Genetics, Inc. (NASDAQ:SGEN). Balyasny Asset Limited Liability Com owns 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 14,890 shares. Tokio Marine Asset Mngmt invested in 0.27% or 29,500 shares. Hall Laurie J Trustee has invested 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). The Pennsylvania-based Glenmede Tru Na has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Griffin Asset Mngmt stated it has 4,775 shares or 0.05% of all its holdings. State Of Alaska Department Of Revenue has invested 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Van Eck Assoc has 135,181 shares for 0.04% of their portfolio. Bluecrest Mgmt Limited stated it has 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). Mckinley Management Ltd Llc Delaware accumulated 2,323 shares or 0.01% of the stock. Commerzbank Aktiengesellschaft Fi reported 50,037 shares.

The stock decreased 0.30% or $0.21 during the last trading session, reaching $69. About 133,636 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 15.50% since June 13, 2017 and is downtrending. It has underperformed by 28.07% the S&P500. Some Historical SGEN News: ; 16/04/2018 – CELLDEX THERAPEUTICS INC – NO SIGNIFICANT ADVANTAGE FOR GLEMBATUMUMAB VEDOTIN IN KEY SECONDARY ENDPOINTS; 07/03/2018 – Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma; 26/04/2018 – SEATTLE GENETICS INC – SEES 2018 RESEARCH AND DEVELOPMENT (R&D) $530 MLN TO $580 MLN; 24/04/2018 – ADC Therapeutics’ PBD-based anti-HER2 antibody drug conjugate terminated due to safety; 20/03/2018 – SEATTLE GENETICS: FDA APPROVES EXPANDED USE FOR ADCETRIS; 17/05/2018 – Seattle Genetics Presenting at Conference Jun 3; 05/04/2018 – Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018; 21/03/2018 – Seattle Genetics Closes Below 50-Day Moving Average: Technicals; 12/04/2018 – Seattle Genetics Presenting at Conference Apr 16; 26/04/2018 – SEATTLE GENETICS INC – ECHELON-2 DATA EXPECTED IN 2018

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: